Post by
francoisl13 on Sep 14, 2023 2:18pm
News required to move price upwards
Now that short term credit facility concerns are behind us, at least until end of November, KNE needs to present some good news to the market in order to gains some momentum. Here are the one I see as short term priorities (ie.: before end of October/November);
1. News about the first Coactiv+ order from Progenacare shortly followed by one about the first product delivery;
2. News about the start of the DispersinB phase 1 trial with DoD;
3. News on the DispersinB clinical trial for acne with the UofMiami.
All of the above needs to be announced as soon as possible in order to meet previously published expectations by the company.
P.S.I'm still puzzled by the fact that Progenacare (and Salud Pharma) are not posting their deal with Kane about the Coactiv+ product and don't even show the product on their respective website.
GLTA
Comment by
KevinOleary on Oct 06, 2023 10:02pm
1 How about waiting until the plant is able to produce coactiv in January? The dispersin trial started. You're far from being on top of this investment, so I get it that you're puzzled.
Comment by
RoyMax123 on Oct 10, 2023 1:27pm
And what surprise me is they expect to clean up the balance sheet and have some cash left with the sale of the animal health business, which is more than I expected
Comment by
francoisl13 on Oct 10, 2023 10:06pm
You are my shining star kevinoleary! Thanks for your very useful post. You're the type of person we all need on a forum. Now, take your pills and go to bed. Good night.